Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.55 |
| ▸ | FNTB | P49356 | 14/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9051605 | 0.99 | FNTA (0.54) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| SCHEMBL5891919 | 0.75 | FNTA (0.55) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| SCHEMBL3500034 | 0.75 | CYP11B1 (0.53) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| Hydrochloric Acid SCHEMBL8541204 | 0.74 | FNTA (0.55) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| Hydrochloric Acid SCHEMBL8368375 | 0.74 | CYP11B1 (0.52) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| SCHEMBL6712710 | 0.74 | FNTA (0.47) | FNTAFNTBKCNH2 | |
| SCHEMBL6709667 | 0.72 | FNTA (0.46) | FNTAFNTBKCNH2 | |
| SCHEMBL8506339 | 0.72 | FNTA (0.61) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| Hydrochloric Acid SCHEMBL8505325 | 0.71 | FNTA (0.60) | FNTAFNTBKCNH2PGGT1BCYP11B1 | |
| SCHEMBL6714988 | 0.71 | FNTA (0.53) | FNTAFNTBKCNH2PGGT1BCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | claimed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | FNTA 1/4885FNTB 12/4885KCNH2 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.